Auswirkungen der Danazol-Therapie bei Endometriose auf Blutbild und Gerinnung

Karl-Werner Schweppe, K W Schweppe, C Ebert, Ch. Ebert, U Cirkel
Geburtshilfe und Frauenheilkunde · 1988 · vol. 48(09) , pp. 634–636 · doi:10.1055/s-2008-1026554 · PMID:3181711 · W2003538559
article OA: closed CC0 ⤵ 2 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Danazol treatment for endometriosis over six months increased hemoglobin, hematocrit, and antithrombin III while decreasing alpha-2-macroglobulin, fibrinogen, and plasminogen, indicating potential hypocoagulability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This study investigated the effects of danazol, an ethisterone derivative, on blood count and coagulation in 62 endometriosis patients treated for 6 months with 600 mg/day. Blood parameters and coagulation status were measured before and during therapy, and the key findings were a significant increase in hemoglobin and hematocrit, with no changes in red blood cell, leukocyte, or platelet counts or several coagulation times and factors (including thrombin time, thromboplastin times, factor VII, VIII, X, XII, and alpha-1-antitrypsin). Antithrombin III increased and alpha-2-macroglobulin decreased, while only fibrinogen decreased to pathological ranges and plasminogen increased significantly (p<0.01). The authors conclude that the partly contradictory coagulation-marker changes suggest hypocoagulability under danazol, but the clinical relevance remains unclear. This paper is centrally about endometriosis — it specifically examines how danazol therapy affects blood counts and coagulation status in endometriosis patients.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Over a six-month period, 62 endometriosis patients were given 600 mg per day of the ethisterone derivative danazol. Blood count and coagulation status were checked before and during treatment. There was a significant increase (p less than 0.05) in hemoglobin and hematocrit. There were no changes in RBC, leukocyte count, or thrombocyte count; the mean cellular erythrocyte volume, thrombin time, thromboplastin time, and partial thromboplastin time also remained unchanged, as did factors VII, VIII, X, XII, and alpha-1-antitrypsin. Antithrombin III levels increased, while alpha-2-macroglobulin values decreased. Only the drop in fibrinogen, to pathologic values, and the increase in plasminogen reached significant levels (p less than 0.01). These in part contradictory changes suggest that hypocoagulability occurs under danazol medication; however, its clinical relevance is unclear.
Full text 2,044 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS DOI: 10.1055/s-2008-1026554 Auswirkungen der Danazol-Therapie bei Endometriose auf Blutbild und Gerinnung Effects of Danazol Therapy on Blood Count and Coagulation in Endometriosis CasesPublication History Publication Date: 17 June 2008 (online) Zusammenfassung Das Ethisteronderivat Danazol wurde bei 62 Endometriosepatientinnen über 6 Monate in einer Dosis von 600 mg/die angewendet. Vor und während der Behandlung wurden Blutbild und Gerinnungsstatus überprüft. Hämoglobin und Hämatokrit stiegen eindeutig (p <0,05) an. Keine Veränderungen traten auf bei Erythrozyten-, Leukozyten- und Thrombozyten-Zahl; unverändert blieben auch das mittlere zelluläre Erythrozyten-Volumen, Thrombinzeit, Thromboplastinzeit und partielle Thromboplastin-zeit sowie die Faktoren VII, VIII, X, XII und α1-Antitrypsin. Antithrombin III stieg an; α2-Makroglobulin fiel ab. Lediglich die Fibrinogenerniedrigung in pathologische Bereiche und der Plasminogenanstieg erreichten ein signifikantes Niveau (p <0,01). Diese z. T. gegensinnigen Veränderungen sprechen eher für eine Hypokoagulabilität unter Danazol-Medikation, deren klinische Relevanz allerdings unklar ist. Abstract Over a six-month period, 62 endometriosis patients were given 600 mg per day of the ethisterone derivative danazol. Blood count and coagulation Status were checked before and during treatment. There was a significant increase (p <0.05) in hemoglobin and hematocrit. There were no changes in RBC, leukocyte count, or thrombocyte count; the mean cellular erythrocyte volume, thrombin time, thromboplastin time, and partial thromboplastin time also remained unchanged, as did factors VII, VIII, X, XII, and alpha-1-antitrypsin. Antithrombin III levels increased, while alpha-2-macroglobulin values decreased. Only the drop in fibrinogen, to pathologic values, and the increase in Plasminogen reached significant levels (p <0.01). These in part contradictory changes suggest that hypocoagulability occurs under danazol medication; however, its clinical relevance is unclear.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Blood Cell Count Blood Coagulation Disorders Danazol Endometriosis Genital Neoplasms, Female Hematocrit Hemoglobinometry Pregnadienes Adult Blood Cell Count Blood Coagulation Disorders Blood Coagulation Factors Blood Coagulation Factors Danazol Danazol Endometriosis Endometriosis Female Genital Neoplasms, Female Genital Neoplasms, Female

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-19T06:14:56.452680+00:00
openalex
last seen: 2026-05-11T06:50:19.369421+00:00
pubmed
last seen: 2026-05-13T22:09:20.810540+00:00
License: CC0 · commercial use OK